Document is current
Any future updates will be listed below
-
Authors
Takao, Sumiko https://orcid.org/0000-0001-5573-1677
Morell, Victor https://orcid.org/0000-0002-7071-1030
Uni, Masahiro https://orcid.org/0009-0005-8418-0743
Slavit, Alicia
Rha, Sophia
Cheng, Shuyuan
Schmalbrock, Laura K. https://orcid.org/0000-0002-6080-6175
Brown, Fiona C.
Beneyto-Calabuig, Sergi https://orcid.org/0000-0003-3773-8239
Koche, Richard P. https://orcid.org/0000-0002-6820-5083
Velten, Lars https://orcid.org/0000-0002-1233-5874
Kentsis, Alex https://orcid.org/0000-0002-8063-9191
- License Information
-
More Information
Article History
Received: 9 August 2024
Accepted: 17 March 2025
First Online: 3 April 2025
Competing interests
: The authors declare no competing interests. A.K. is a consultant to Rgenta, Novartis, Blueprint Medicines, and Syndax.
